Complete and announce analyses of secondary endpoint data for the 100-303 COVID Trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 Feb 2021
- Due
- 31 Mar 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Analyses of the secondary endpoint data are anticipated to be completed and announced before the end of the first quarter of 2021.”
What we found
Evidence strength A What the grades mean
The company failed to meet the Q1 2021 deadline, subsequently pushing the anticipated completion date for the secondary endpoint analyses to the end of May 2021.
-
A Diffusion Pharmaceuticals Inc. 10-Q filed 2021-05-07
“Evaluation of secondary endpoint data from this safety and tolerability trial remains ongoing and we anticipate topline data from these secondary endpoint analyses will be completed and announced before the end of May 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- 100-303 COVID Trial secondary endpoint data analyses
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Diffusion Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CRVO-023746 · Corrections policy